GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (FRA:C5G) » Definitions » Cash From Discontinued Investing Activities

Orexo AB (FRA:C5G) Cash From Discontinued Investing Activities : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Orexo AB Cash From Discontinued Investing Activities?

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Orexo AB's cash from discontinued investing activities for the three months ended in Sep. 2024 was €0.00 Mil. It means Orexo AB received €0.00 Mil from discontinued investing activities. Orexo AB's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Orexo AB Cash From Discontinued Investing Activities Historical Data

The historical data trend for Orexo AB's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB Cash From Discontinued Investing Activities Chart

Orexo AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash From Discontinued Investing Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Orexo AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash From Discontinued Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Orexo AB Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of Orexo AB's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Orexo AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (FRA:C5G) » Definitions » Cash From Discontinued Investing Activities
Comparable Companies
OSTO:ENZY OSTO:MOB XSAT:DICOT OSTO:ERMA OSTO:NANEXA OSTO:VIVE XSAT:ACUC OSTO:KLAR OSTO:TOL OSTO:NEWBRY ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA XSWX:SDZ NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
ORXOY:USA ORXOF:USA ORX:Sweden
Address
Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105
Website
https://www.orexo.com
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB Headlines

No Headlines